Fair Value Calculator Fair Value Calculator
EN DE

8143 (8143) Fair Value & Analysis

Healthcare · Market cap HK$82.3M

8 8143 8143 · HK
PriceHK$0.0730
Fair ValueHK$0.0489
Upside-33.0%
Quality40/100
Watch 8143 for free — get notified when fair value or trend changes. Watch for free
Evidence: Medium Range HK$0.0416 – HK$0.0562

Fair value as of: Jul 2, 2026

From 9 valuation models · updated today

Share price −8.8% over the past month.

Price vs Fair Value (12 months)

HK$0.2420 HK$0.0450 Fair Value HK$0.0489 Jun 2025 Jul 2026

12‑month range HK$0.0450 – HK$0.2420 · fair‑value band HK$0.0416 – HK$0.0562 · the HK$0.0730 price screens above the HK$0.0489 fair value. As of Jul 2, 2026.

✦ Which stocks are undervalued right now? Check free Discover now →

Analysis

8143 (8143) currently trades at HK$0.0730, while our model-based Fair Value estimate is HK$0.0489 — implying the stock looks roughly 33.0% overvalued today. We read business quality at 40/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: medium).

Over the trailing twelve months, 8143 generated revenue of HK$20.1M at a net margin of -62.4%. Revenue grew 68.2% year over year. The balance sheet holds a net cash position of HK$12.9M. Fundamentals as of Jul 2, 2026

Key figures & financial health

Revenue (TTM) HK$20.1M
Revenue growth (YoY) +68.2%
Net margin -62.4%
Return on equity -2,221%
Free cash flow HK$2.6M FY2025
Operating margin -38.4%
More key figures
EPS (TTM) HK$-0.0300
Net cash HK$12.9M FY2026

Figures from reported company fundamentals (EODHD) · as of Jul 2, 2026. TTM = trailing twelve months.

Revenue & earnings trend

FY2022 – FY2026 · reported fiscal years

8143 reported revenue of HK$20.1M in FY2026 versus HK$54.2M in FY2022, a compound −22.0%/yr. Reported net income was −HK$12.5M in FY2026.

Revenue −22.0%/yr
FY22 HK$54.2M
FY23 HK$55.4M
FY24 HK$39.0M
FY25 HK$16.1M
FY26 HK$20.1M
Net income
FY22 −HK$12.7M
FY23 −HK$5.9M
FY24 −HK$17.1M
FY25 −HK$10.1M
FY26 −HK$12.5M

Is 8143 fairly valued? → Check now

Similar stocks

6 more Medical Care Facilities stocks, each showing price versus our Fair Value estimate (as of Jul 2, 2026).

Stock Price Fair Value vs Fair Value
HCA Healthcare, Inc H1CA34 R$96.00 R$25.67 -73%
Fresenius SE FSNUY $11.30 $8.61 -24%
5225 5225 8.67 MYR 3.08 MYR -64%
IHHHF IHHHF $1.71 $0.7400 -57%
Tenet Healthcare Corporation THC $178.75 $300.86 +68%
Rede D'Or São Luiz S.A RDOR3 R$33.83 R$46.94 +39%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued Blue-Chip StocksUndervalued Small-Cap Stocks

Frequently asked questions

Is 8143 (8143) undervalued?
As of Jul 2, 2026, our model estimates a fair value of HK$0.0489 versus a price of HK$0.0730 — about −33% (overvalued). Model-based estimate, not financial advice.
What is the fair value of 8143?
Our model-based fair value for 8143 is HK$0.0489 (as of Jul 2, 2026), built from audited fundamentals. The current price is HK$0.0730.
What is the quality score of 8143?
8143 has a Quality Score of 40/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.
What is the revenue of 8143 (8143)?
8143 reported trailing-twelve-month revenue of about HK$20.1M (latest available figure, as of Jul 2, 2026).
What is the net profit margin of 8143?
The net profit margin of 8143 is about -62.4%, meaning it is currently running at a net loss. Based on the latest reported figures.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.